Lipid-lowering therapy in high-risk persons.
Randomized, double-blind, placebo-controlled studies and observational studies have demonstrated that statins reduce mortality and major cardiovascular events in high-risk persons with hypercholesterolemia. The Heart Protection Study showed that statins reduced mortality and major cardiovascular events in high-risk persons, regardless of the initial level of serum lipids, age, or gender. Lipid-lowering therapy reduces cardiovascular morbidity and mortality in high-risk persons, forming the basis for the updated National Cholesterol Education Program (NCEP) III guidelines.